Anjana Pillai to Bevacizumab
This is a "connection" page, showing publications Anjana Pillai has written about Bevacizumab.
Connection Strength
0.475
-
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology. 2025 Mar 01; 81(3):837-852.
Score: 0.212
-
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
Score: 0.210
-
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
Score: 0.053